Novartis Consumer Health Profits Boosted By Sales, Division Merger
This article was originally published in The Tan Sheet
Sales expansion and costs savings from the merger of Novartis' Self-Medication and Nutrition businesses drove Consumer Health division profits in the first six months of 1999, the firm announced Aug. 26.
You may also be interested in...
Novartis said its new OTC athlete's foot medication Lamisil AT Cream is the only nonprescription medication that cures athlete's foot with one week of treatment in its announcement that FDA has approved the Rx-to-OTC switch.
NOVARTIS MERGING SELF-MEDICATION AND NUTRITION UNITS into a new global Consumer Health division and focusing the nutrition segment on health nutrition and functional food, the company announced Aug. 27. Combining the worldwide over-the-counter drug and nutrition businesses "will help us accelerate our pace in shaping and penetrating new market segments such as the emerging field of functional food, whose size is estimated to double to over $20 bil. U.S. dollars in annual sales within four years," Novartis said.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC